CF PharmTech, Inc. (HKG:2652)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
37.08
-0.26 (-0.70%)
Last updated: Mar 5, 2026, 3:15 PM HKT
-21.11%
Market Cap 15.36B
Revenue (ttm) 647.51M
Net Income (ttm) 29.75M
Shares Out 411.48M
EPS (ttm) 0.08
PE Ratio 516.40
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 125,500
Average Volume 235,152
Open 37.78
Previous Close 37.34
Day's Range 36.76 - 38.50
52-Week Range 27.20 - 48.80
Beta n/a
RSI 56.63
Earnings Date n/a

About CF PharmTech

CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs in the field of respiratory diseases in China. It offers Shufeimin, an azelastine hydrochloride and fluticasone propionate nasal spray; ChangQi, a budesonide inhalation suspension solution; ChangShu, a salbutamol sulfate inhalation solution; and piezoelectric mesh nebulizer, electric nasal cleaner, BFS hypertonic and physiological seawater nasal cleansing fluid products under the ChangShu name. The company also develops products for the treatment o... [Read more]

Sector Healthcare
Founded 2007
Employees 574
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2652
Full Company Profile

Financial Performance

In 2024, CF PharmTech's revenue was 607.75 million, an increase of 9.23% compared to the previous year's 556.42 million. Earnings were 21.09 million, a decrease of -33.53%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.